Patents by Inventor John H. Musser

John H. Musser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170232035
    Abstract: The present disclosure relates to polygalacturonan rhamnogalacturonan (PGRG1) compositions, as well as methods of making and methods of using said compositions in medicinally useful and pharmaceutically useful forms. Specifically, the present disclosure provides purified PGRG1 compositions isolated from roots of the Astragalus genus of plants, and more particularly from the species Astragalus membranaceus, as well as PGRG1 compositions having a weight average molecular weight of at least 40 kiloDaltons (kDa).
    Type: Application
    Filed: August 17, 2015
    Publication date: August 17, 2017
    Applicant: Pharmagenesis, Inc.
    Inventors: John H MUSSER, Jinhua AN
  • Publication number: 20160038454
    Abstract: Intravenous formulations of triptolide and triptolide derivatives are disclosed for use in immunomodulation and anti-proliferative agents.
    Type: Application
    Filed: March 15, 2014
    Publication date: February 11, 2016
    Inventors: Jinhua AN, Weiguo HE, John M. Fidler, John H. Musser
  • Patent number: 8728543
    Abstract: The teachings provided herein generally relate to the preparation and uses of compositions comprising extracts of Astragalus membranaceus. The extracts are prepared from Astragalus membranaceus and can comprise, for example, an acid-modified arabinogalactan protein composition having an arabinose:galactose ratio ranging from about 3.5:1 to about 5.0:1, from about 5% to about 10% rhamnose, from about 15% to about 20% galactose, and from about 10% to about 15% glucose. The compositions can be used in the treatment of idiopathic thrombocytopenic purpura and the formulation of medicaments for such treatments.
    Type: Grant
    Filed: February 7, 2012
    Date of Patent: May 20, 2014
    Assignee: Ecopharm Corporation
    Inventors: Jinhua An, John M. Fidler, John H. Musser
  • Patent number: 8617906
    Abstract: The identification of triptolide target molecules is described. Also described are methods of screening triptolide-related compounds for binding to these molecules, including screening for enhanced and/or selective binding, and expression analysis of the target molecules in normal and in diseased tissue.
    Type: Grant
    Filed: October 12, 2005
    Date of Patent: December 31, 2013
    Assignee: Pharmagenesis, Inc.
    Inventors: John M. Fidler, John H. Musser
  • Patent number: 8426616
    Abstract: Disclosed are compounds based on lactone ring modifications of triptolide and hydroxylated triptolide, for use in therapy, such as antiproliferative, anticancer, and immunosuppressive therapy.
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: April 23, 2013
    Assignee: Pharmagenesis, Inc.
    Inventors: Hongwei Yuan, John H. Musser, Dongcheng Dai
  • Patent number: 8324174
    Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: December 4, 2012
    Assignee: Onyx Therapeutics, Inc.
    Inventors: Mark S. Smyth, Guy J. Laidig, Ronald T. Borchardt, Barry A. Bunin, Craig M. Crews, John H. Musser
  • Publication number: 20120277146
    Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
    Type: Application
    Filed: March 2, 2012
    Publication date: November 1, 2012
    Applicant: ONYX PHARMACEUTICALS INC.
    Inventors: Mark S. Smyth, Guy J. Laidig, Ronald T. Borchardt, Barry A. Bunin, Craig M. Crews, John H. Musser
  • Patent number: 8268882
    Abstract: Disclosed are compounds based on C- and D-ring modifications of triptolide and hydroxylated triptolide, for use in therapy, such as antiproliferative, anticancer, and immunosuppressive therapy.
    Type: Grant
    Filed: February 4, 2010
    Date of Patent: September 18, 2012
    Assignee: Pharmagenesis, Inc.
    Inventor: John H. Musser
  • Publication number: 20120141412
    Abstract: The teachings provided herein generally relate to the preparation and uses of compositions comprising extracts of Astragalus membranaceus. The extracts are prepared from Astragalus membranaceus and can comprise, for example, an acid-modified arabinogalactan protein composition having an arabinose:galactose ratio ranging from about 3.5:1 to about 5.0:1, from about 5% to about 10% rhamnose, from about 15% to about 20% galactose, and from about 10% to about 15% glucose. The compositions can be used in the treatment of idiopathic thrombocytopenic purpura and the formulation of medicaments for such treatments.
    Type: Application
    Filed: February 7, 2012
    Publication date: June 7, 2012
    Inventors: JINHUA AN, John M. Fidler, John H. Musser
  • Publication number: 20120101025
    Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
    Type: Application
    Filed: December 30, 2011
    Publication date: April 26, 2012
    Applicant: ONYX THERAPEUTICS, INC.
    Inventors: Mark S. Smyth, Guy J. Laidig, Ronald T. Borchardt, Barry A. Bunin, Craig M. Crews, John H. Musser, Kevin D. Shenk, Peggy A. Radel
  • Publication number: 20120101026
    Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
    Type: Application
    Filed: December 30, 2011
    Publication date: April 26, 2012
    Applicant: ONYX THERAPEUTICS, INC.
    Inventors: Mark S. Smyth, Guy J. Laidig, Ronald T. Borchardt, Barry A. Bunin, Craig M. Crews, John H. Musser, Kevin D. Shenk, Peggy A. Radel
  • Publication number: 20120101050
    Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
    Type: Application
    Filed: December 22, 2011
    Publication date: April 26, 2012
    Applicant: Onyx Therapeutics, Inc.
    Inventors: Mark S. Smyth, Guy J. Laidig, Ronald T. Borchardt, Barry A. Bunin, Craig M. Crews, John H. Musser
  • Patent number: 8137710
    Abstract: The teachings provided herein generally relate to the preparation and uses of compositions comprising extracts of Astragalus membranaceus. The extracts are prepared from Astragalus membranaceus and can comprise, for example, an acid-modified arabinogalactan protein composition having an arabinose:galactose ratio ranging from about 3.5:1 to about 5.0:1, from about 5% to about 10% rhamnose, from about 15% to about 20% galactose, and from about 10% to about 15% glucose. The compositions can be used in the treatment of idiopathic thrombocytopenic purpura and the formulation of medicaments for such treatments.
    Type: Grant
    Filed: December 15, 2009
    Date of Patent: March 20, 2012
    Assignee: EcoPharm Corporation
    Inventors: Jinhua An, John M. Fidler, John H. Musser
  • Patent number: 8129346
    Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
    Type: Grant
    Filed: April 14, 2005
    Date of Patent: March 6, 2012
    Assignee: Onyx Therapeutics, Inc.
    Inventors: Mark S. Smyth, Guy J. Laidig, Ronald T. Borchardt, Barry A. Bunin, Craig M. Crews, John H. Musser
  • Patent number: 8088741
    Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsinlike activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
    Type: Grant
    Filed: May 9, 2005
    Date of Patent: January 3, 2012
    Assignee: Onyx Therapeutics, Inc.
    Inventors: Mark S. Smyth, Guy J. Laidig, Ronald T. Borchardt, Barry A. Bunin, Craig M. Crews, John H. Musser, Kevin D. Shenk, Peggy A. Radel
  • Publication number: 20110288166
    Abstract: Disclosed are compounds based on C- and D-ring modifications of triptolide and hydroxylated triptolide, for use in therapy, such as antiproliferative, anticancer, and immunosuppressive therapy.
    Type: Application
    Filed: February 4, 2010
    Publication date: November 24, 2011
    Inventor: John H. Musser
  • Patent number: 8048914
    Abstract: Methods for extraction, isolation, and purification of therapeutically useful compounds from Tripterygium wilfordii are described. Extraction steps employing aqueous base and a hydrocarbon solvent, respectively, are found to increase the efficiency of the process and reduce the amount of material that must be removed by chromatography.
    Type: Grant
    Filed: February 7, 2005
    Date of Patent: November 1, 2011
    Assignee: Pharmagenesis, Inc.
    Inventors: Jinhua An, Rensheng Xu, John H. Musser
  • Publication number: 20110076293
    Abstract: Variously substituted carbonate and carbamate derivatives of triptolide compounds have good aqueous solubility and convert to biologically active compounds in vivo, at a rate which can be modulated by varying the substitution on the prodrug. The prodrugs are useful as immunosuppressive, anti-inflammatory and anticancer agents.
    Type: Application
    Filed: December 6, 2010
    Publication date: March 31, 2011
    Inventors: Dongcheng Dai, John H. Musser, Edwin S. Lennox
  • Patent number: 7863464
    Abstract: Disclosed are compounds based on lactone ring modifications of triptolide and hydroxylated triptolide, for use in therapy, such as antiproliferative, anticancer, and immunosuppressive therapy.
    Type: Grant
    Filed: March 2, 2005
    Date of Patent: January 4, 2011
    Assignee: Pharmagenesis, Inc.
    Inventors: Hongwei Yuan, John H. Musser, Dongcheng Dai
  • Publication number: 20100331554
    Abstract: Disclosed are compounds based on lactone ring modifications of triptolide and hydroxylated triptolide, for use in therapy, such as antiproliferative, anticancer, and immunosuppressive therapy.
    Type: Application
    Filed: September 2, 2010
    Publication date: December 30, 2010
    Inventors: Hongwei Yuan, John H. Musser, Dongcheng Dai